Lilly's Alzheimer's Innovative Therapy Kisunla™ (Donanemab) Included in Guangzhou's 'Suixinbao Zhujiang Medicine Assurance' Commercial Health Insurance

"Suixin Bao" Series of Commercial Health Insurance: As part of the Guangzhou municipal government’s ongoing efforts to build an open, multi-layered medical security system, a collaborative mechanism involving government facilitation, hospital participation, and commercial insurance operation has been established. This initiative strongly supports the integration and supplementation of commercial health insurance with the basic medical insurance system. As an innovative commercial health insurance product guided by the Guangzhou municipal government and operated by insurance institutions, "Suixin Bao" aims to effectively bridge policy coordination and market mechanisms, filling gaps in areas not adequately covered by basic medical insurance—particularly playing a crucial supplementary role in providing coverage for high-value innovative drugs and medical devices. Its core objectives include: addressing gaps in medical insurance, reducing catastrophic healthcare expenses for residents, enhancing fairness in medical security, while also promoting high-quality development of the pharmaceuticals industry.

Ji Neng Da^®The inclusion of "Sui Xin Bao Zhujiang Pharmaceutical Peace of Mind" helps more Alzheimer's patients receive local惠民保 (Hui Min Bao) support to reduce financial pressure and provides practical assurance for early diagnosis and treatment. At the same time, this explores a new path for industry innovation and payment system linkage. This not only brings hope to patients and their families but also reflects significant progress in Chinese society towards building a more inclusive and sustainable healthcare security system.

Ji Neng Da^®It is a revolutionary drug applicable to the early stage of Alzheimer's disease, targeting the pathological mechanism of the disease and capable of slowing down the progression. As a breakthrough therapy, Category 1 new drug,Ji Neng Da^®Approved by the National Medical Products Administration (NMPA) of China on December 17, 2024, for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease in adults.

With the in-depth advancement of the "Healthy China 2030 Plan Outline," the national level is paying increasing attention to the coordinated development of basic medical insurance and commercial insurance. Policies encourage the exploration of "basic insurance + commercial insurance" multi-payment pathways, promoting the formation of a new guarantee pattern led by the government, participated in by the market, and benefiting all citizens. The "Sui Xin Bao" series of commercial insurances are practical measures under this policy orientation, encouraging local innovation in pharmaceuticals.

As China's population aging intensifies, the family caregiving pressure and socio-economic burden caused by Alzheimer's disease are increasingly加重. Eli Lilly and Company will continue to work with stakeholders such as the government, industry partners, and professional institutions to deepen local cooperation and innovate保障 models, accelerate the availability of innovative drugs for Chinese patients, and jointly build a dementia-friendly society to collectively address the challenges of aging.

All trademarks or trade names mentioned in this article are owned by Eli Lilly and Company. If trademarks or trade names of other companies are mentioned, their ownership belongs to their respective owners. For ease of reading, the ® and ™ symbols are not used for the trademarks and trade names mentioned in this article; however, this does not mean that Eli Lilly and Company or (where applicable) the respective owners will not assert their rights to these trademarks and trade names to the fullest extent permitted by applicable law. Our use or display of trademarks and trade names of other companies does not imply any relationship with these companies or suggest endorsement or sponsorship by them.

PP-MG-CN-3886